Correlation Between Santhera Pharmaceuticals and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Santhera Pharmaceuticals and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Santhera Pharmaceuticals and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Santhera Pharmaceuticals Holding and Molecular Partners AG, you can compare the effects of market volatilities on Santhera Pharmaceuticals and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Santhera Pharmaceuticals with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Santhera Pharmaceuticals and Molecular Partners.

Diversification Opportunities for Santhera Pharmaceuticals and Molecular Partners

-0.32

Correlation Coefficient

Santhera Pharmaceuticals  Molecular Partners

Very good diversification

The 3 months correlation between Santhera and Molecular is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Santhera Pharmaceuticals Holdi and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Santhera Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Santhera Pharmaceuticals Holding are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Santhera Pharmaceuticals i.e., Santhera Pharmaceuticals and Molecular Partners go up and down completely randomly.

Pair Corralation between Santhera Pharmaceuticals and Molecular Partners

Assuming the 90 days trading horizon Santhera Pharmaceuticals Holding is expected to generate 1.01 times more return on investment than Molecular Partners. However, Santhera Pharmaceuticals is 1.01 times more volatile than Molecular Partners AG. It trades about 0.39 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.12 per unit of risk. If you would invest  835.00  in Santhera Pharmaceuticals Holding on September 27, 2024 and sell it today you would earn a total of  309.00  from holding Santhera Pharmaceuticals Holding or generate 37.01% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Santhera Pharmaceuticals Holdi  vs.  Molecular Partners AG

Santhera Pharmaceuticals

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Santhera Pharmaceuticals Holding are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Santhera Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Molecular Partners showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Santhera Pharmaceuticals and Molecular Partners

The main advantage of trading using opposite Santhera Pharmaceuticals and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Santhera Pharmaceuticals position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Santhera Pharmaceuticals Holding and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.